Amy Emerson

Amy Emerson, the CEO of Lykos Therapeutics, has stepped down from her role at the company, the WSJ reported. This announcement comes nearly a month after the Food and Drug Administration (FDA) rejected Lykos’s application for its ecstasy-based therapy intended to treat post-traumatic stress...

Lykos Therapeutics has announced a strategic reorganization in response to the recent FDA decision regarding its new drug application for MDMA capsules – also known as Ecstasy or Molly – intended for treating post-traumatic stress disorder (PTSD) in adults. New Senior Medical Advisor As...

The Food and Drug Administration (FDA) this week declined to approve the use of MDMA — popularly known as Ecstasy or Molly — for MDMA-assisted therapy for treating PTSD, disappointing many Americans who suffer with intractable mental health conditions and had pinned their hopes on the treatment....

The potential of MDMA-assisted therapy (MDMA-AT) for treating post-traumatic stress disorder (PTSD) has garnered significant attention, including many scientific studies that indicate promising results. However, while the majority of the results suggest safety and efficacy, researchers emphasize...